A study of SAR444245 with or without other anticancer therapies for the treatment of adults and adolescents with relapsed or refractory B cell lymphoma (Master Protocol) [Pegathor Lymphoma 205]

Trial Identifier: ACT16941
Sponsor: Sanofi
Collaborator:
Merck Sharp & Dohme LLC.
Start Date: December 2021
Primary Completion Date: September 2023
Study Completion Date: September 2024
Condition: Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
ARGENTINA, Buenos Aires CABA, Buenos Aires, ARGENTINA, 1430
CHILE Temuco, CHILE, 4800827
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 7500921
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 7500653
CHILE, Valparaíso Vina del Mar, Valparaíso, CHILE, 2540488
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08036
SPAIN, Barcelona [Barcelona] Hospitalet de Llobregat, Barcelona [Barcelona], SPAIN, 08908
SPAIN, Madrid, Comunidad de Madrid / Madrid, Madrid, Comunidad de, SPAIN, 28040